Astec Lifesciences
635.95
-21.90(-3.33%)
Market Cap₹1,417.00 Cr
PE Ratio-16.48
IndustryChemicals
Company Performance:
1D-3.33%
1M-10.45%
6M-26.29%
1Y-31.80%
5Y-41.20%
View Company Insightsright
More news about Astec Lifesciences
05Sept 25
Astec LifeSciences Reports Strong FY21 Results, Recommends 15% Final Dividend
Astec LifeSciences Limited announced strong financial results for FY 2020-21. Standalone profit increased by 36.28% to ₹6,469.25 lakh, while revenue from operations grew by 6.25% to ₹55,487.21 lakh. The company's Basic Earnings Per Share rose to ₹33.05. The Board recommended a final dividend of 15% (₹1.50 per share), subject to shareholder approval. The company maintains a healthy financial position with a debt-equity ratio of 0.61 and a net worth of ₹308.70 crore. The 27th Annual General Meeting is scheduled for July 28, 2021.
 no imag found
01Aug 25
Godrej Agrovet Boosts Stake in Astec LifeSciences to 67.03% via Market Purchase and Rights Issue
Godrej Agrovet Limited increased its shareholding in Astec LifeSciences Limited from 63.36% to 67.03% through open market purchases and participation in a rights issue. The acquisition, completed on July 29, 2025, involved 25,31,229 additional shares, bringing Godrej Agrovet's total holding to 1,49,35,245 shares. Astec LifeSciences' equity share capital expanded from Rs. 19.61 crore to Rs. 22.28 crore. Godrej Agrovet filed a disclosure under Regulation 29(2) of SEBI regulations on July 31, 2025.
 no imag found
28Jul 25
Astec Lifesciences Reports Q1 Revenue Growth Despite Continued Losses
Astec Lifesciences, an agrochemical sector company, released its Q1 financial results. Revenue increased to ₹911.00 million from ₹694.00 million year-over-year, a 31.27% growth. The company reported a net loss of ₹330.00 million, an improvement from the previous year's ₹397.00 million loss. EBITDA loss significantly narrowed to ₹110.00 million from ₹463.00 million in the same quarter last year, showing a 76.24% reduction.
 no imag found
02Jul 25
Astec Lifesciences Announces ₹249.35 Crore Rights Issue
Astec Lifesciences, an agrochemical sector company, has filed an offer letter for a rights issue to raise ₹249.35 crore. The company has not disclosed specific terms, including share price, rights entitlement ratio, or the intended use of funds. The timeline for the rights issue is also yet to be announced. This move could potentially fund expansion plans, reduce debt, invest in R&D, or strengthen the company's balance sheet.
 no imag found
30Jun 25
Astec LifeSciences Announces ₹249.35 Crore Rights Issue at ₹890 Per Share
Astec Lifesciences, an agrochemical company, has announced a rights issue to raise ₹249.35 crores. The issue price is set at ₹890 per share for 28,01,673 shares, with an issue ratio of 1:7. The record date is July 4, 2025, and the issue will be open from July 14 to July 28, 2025. This move aims to strengthen the company's financial position and potentially fund growth initiatives.
 no imag found
24Jun 25
Astec Lifesciences Surges 7.5% on ₹250 Crore Rights Issue Approval
Astec Lifesciences' Board of Directors approved a rights issue to raise up to ₹250 crore through fully paid-up equity shares with a face value of ₹10 each. The stock price surged 7.5% to ₹821.50 following the announcement. Key details such as the record date and entitlement ratio are yet to be determined. The rights issue aims to strengthen the company's financial position and potentially fund growth initiatives.
 no imag found
19Jun 25
Astec Lifesciences to Discuss Fundraising Proposal in Upcoming Board Meeting
Astec Lifesciences, an agrochemical sector company, has announced a Board of Directors meeting on June 24 to discuss a fundraising proposal. The specific details of the potential fundraising, including its nature and amount, have not been disclosed. This meeting could have significant implications for the company's financial structure and future growth strategies.
 no imag found
24Apr 25
Astec Lifesciences Reports Widened Losses in Q4 FY2025 Amid Revenue Decline
Astec Lifesciences reported a consolidated net loss of ₹161.00 crore for Q4 FY2025, compared to a ₹9.70 crore loss in Q4 FY2024. Revenue declined 22.3% to ₹1,195.27 crore. Full-year FY2025 results show revenue at ₹3,813.03 crore and net loss at ₹1,347.12 crore. The Enterprise Business saw volume growth but profitability challenges, while CDMO experienced significant volume drops. Despite current challenges, management expects gradual improvement in the coming year.
 no imag found
23Apr 25
Astec Lifesciences Reports Widened Losses in Q4 and FY 2024-25 Amid Revenue Decline
Astec Lifesciences, a leading agrochemical company, reported increased losses for Q4 and FY 2024-25. Q4 saw a net loss of ₹160.79 crore, up from ₹9.70 crore last year, with revenue falling 22.26% to ₹119.53 crore. For FY 2024-25, net loss grew to ₹1,347.12 crore from ₹468.91 crore, while annual revenue dropped 16.78% to ₹381.30 crore. The company's debt-to-equity ratio is 2.36. Performance was impacted by reduced sales, pricing pressures, increased finance costs, and higher depreciation expenses. Management is focusing on cost optimization, product portfolio expansion, and exploring new markets to address challenges.
 no imag found
Astec Lifesciences
635.95
-21.90
(-3.33%)
1 Year Returns:-31.80%
Industry Peers
UPL
741.30
(-0.85%)
PI Industries
3,129.30
(-0.40%)
Sumitomo Chemical
410.35
(-2.30%)
Bayer Crop Science
4,489.90
(+0.71%)
Sharda Cropchem
1,192.30
(+2.55%)
Rallis
270.65
(-0.93%)
Dhanuka Agritech
1,051.00
(-1.63%)
NACL Industries
136.13
(-3.18%)
Bharat Rasayan
1,828.60
(-2.44%)